Overview

National Multicenter, Controlled, Single-blind Study With Two Parallel Groups Evaluating the Safety and Efficacy of Sequential Treatment With Mitoxantrone and Interferon Versus Interferon Alone in Patients With Strong Risk of Progression in the Init

Status:
Unknown status

Trial end date:
2020-11-01

Target enrollment:

Participant gender:

Summary

The relative effectiveness of current treatments and their different mechanisms of action yield to consider more and more that the multiple sclerosis (MS) therapeutic approach must use multiple molecules, both combined and sequential. In this sense, one can assume that the combination of two molecules with different but complementary mechanisms of action, can delay progression of the disease. Mitoxantrone has a powerful action, immediate and total, whereas interferon a selective action, immunomodulatory and delayed.

Phase:

Phase 3

Details

Lead Sponsor:

Rennes University Hospital

Treatments:

Interferon beta-1a
Interferon-beta
Interferons
Mitoxantrone